Conditions: Immune Thrombocytopenic Purpura
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

Detailed description:

Arms:
arm 1: Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks. arm 2: Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Interventions: intervention 1: Fostamatinib Disodium intervention 2: Placebo
Intervention descriptions: intervention 1: Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks. intervention 2: Placebo tablet PO bid (morning and evening)

Protocol document: